Day: February 26, 2021

ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced dosing of the first patient in RAPIDe-1, an on-demand Phase 2 study evaluating the efficacy, safety, and pharmacokinetics of PHVS416 in patients with HAE due to C1-Inhibitor Deficiency type 1 and 2.“The initiation of this trial signifies another step towards developing an oral treatment for hereditary angioedema patients experiencing acute attacks,” said Berndt Modig, chief executive officer and co-founder of Pharvaris. “The importance of providing patients with treatment alternatives to injection cannot be overstated. We...

TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) — Galane Gold Ltd. (“Galane Gold” or the “Company”) (TSX-V: GG; OTCQB: GGGOF) is pleased to announce that it has completed a new 2.2 kilometer adit and has accessed the Galaxy ore body at its Galaxy property (the “Mine”, or “Galaxy”) in South Africa.This represents the final material step required in the Company’s plan to unlock the potential of Galaxy. The three key components of the Galaxy plan were the recommencement of mining at the Princeton ore body (achieved April 2019), the upgrade of the existing processing plant to 50,000 tonnes per month (achieved December 2020) and completing the adit to the Galaxy ore body.(2) The completion of the adit eliminates the historic constraint to underground production at the Mine, that being the capacity of the Woodbine shaft which was limited to 15,000...

Company announcement no. 2-2021Søborg, February 26, 2021Konsolidator hires new Chief Technology OfficerIn a continued effort to strengthen our team, we are pleased to announce that Olov Lindqvist has accepted the position as Chief Technology Officer in Konsolidator. Olov brings in valuable experience to the management team from Saxo Bank as Director and global head of platform development. Olov will be responsible for the growth of our development team and the technological landscape of Konsolidator.Olov has been in Saxo Bank since 2017 and has a Master’s in Computer Science from Chalmers University of Technology. Besides his master’s degree in Computer Science, Olov holds an MBA from Copenhagen Business School. Olov will be reporting to CEO Claus Finderup Grove.Current CTO, Lars Højer Paaske will move to a newly created position as Head...

Company to host conference call at 8:30 a.m. Eastern Time on March 9, 2021 to discuss the resultsManchester, NH, Feb. 26, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Zoom Telephonics, Inc., doing business as Minim (OTCQB: MINM), the creator of innovative internet access products, today announced that it expects to report its financial results for the fourth quarter and year ended December 31, 2020 prior to the market open on Tuesday, March 9, 2021. The company will host a conference call at 8:30 a.m. Eastern Time on March 9, 2021 to discuss the results.Conference Call DetailsTuesday, March 9, 2021 at 8:30 a.m. ETParticipant Dial-In Numbers:United States: (866) 393-7958 International: (706) 643-5255Please dial-in five minutes prior to the start time of the call and provide the operator with conference ID #9895079.A recording...

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28 it is joining the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disease Day®, an international campaign elevating the awareness and public understanding of rare diseases. The initiative’s key message of “Rare is many, rare is strong, rare is proud,” spotlights the more than 300 million people worldwide living with a rare disease, and the awareness efforts focused on bringing them more equitable access to diagnosis, treatment, care and social opportunity.“As the world navigates the ongoing COVID-19 pandemic, people living with rare diseases need our support, now more than ever, and we are especially proud to join with...

TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) — Artificial Intelligence company, AnalytixInsight Inc. (“AnalytixInsight”, or the “Company”) (TSX-V: ALY; OTCQB: ATIXF), announces that its FinTech affiliate, MarketWall, has launched its next-generation trading platform, GEMINA, which is now available as a white label B2B product offering. MarketWall will offer GEMINA to banks and brokers and will demonstrate its proven speed-to-market and cost-saving advantages in the digital transformation of their traditional trading platforms into the era of digital, mobile-enabled, online trading.MarketWall has proven ability in implementing GEMINA in bank-scale applications and has already successfully deployed GEMINA-based solutions for two leading European banks. GEMINA also powers MarketWall’s online financial portal, InvestoPro, which is expected...

ATLANTA, GA, Feb. 26, 2021 (GLOBE NEWSWIRE) — Streamline Health Solutions, Inc. (NASDAQ: STRM) (“Streamline Health”), provider of the eValuator™ Revenue Integrity Program to help healthcare providers proactively address revenue leakage and compliance, today announced the pricing of an underwritten public offering of 8,750,000 shares of its common stock at a purchase price to the public of $1.60 per share. Additionally, in connection with the offering, Streamline Health granted the underwriter a 30-day option to purchase up to an additional 1,312,500 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Streamline Health. The offering is expected to close on or about March 2, 2021, subject to the satisfaction of customary closing conditions.The gross proceeds from the...

NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, March 4, 2021. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, Daniel Luckshire, Chief Financial Officer, and Dr. Dennis Hruby, Chief Scientific Officer.A live webcast of the call will be available on the Company’s website at www.siga.com under the ‘Events & Presentations’ tab in the Investor Relations section, or by clicking here. Participants may also access the call by dialing 877-407-6184 for domestic callers or 201-389-0877 for international callers. Please log in approximately 5-10...

PORTLAND, Ore., Feb. 26, 2021 (GLOBE NEWSWIRE) — Golden Leaf Holdings Ltd. (CSE: GLH) (OTCQB: GLDFF) (“Golden Leaf,” “GLH” or the “Company”), a premier, consumer-driven cannabis company specializing in retail, production, processing, wholesale and distribution, today announces it has signed a non-binding letter of intent to acquire a multi store chain in the Northwest Oregon. These stores are expected to generate at least US$10 million in annual run rate revenue (based on unaudited January 2021 results) and had a net operating margin of 11% (unaudited) during fiscal 2020 (under U.S. GAAP).“We will announce further details about this transaction upon the signing of a definitive purchase agreement,” commented John Varghese, Golden Leaf Executive Chairman.The Company currently anticipates that the consideration for the acquisition...

Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapySOUTH SAN FRANCISCO, Calif., and WARMINSTER, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced the initiation of a Phase 2 clinical trial of Assembly Bio’s investigational hepatitis B virus (HBV) core inhibitor candidate, also known as a capsid inhibitor, vebicorvir (VBR), in combination with Arbutus’ proprietary GalNAc delivered RNAi therapeutic candidate, AB-729, and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy for the treatment of patients with chronic HBV infection. The companies announced a clinical collaboration agreement in August 2020.The randomized,...